BACKGROUND:Linezolid is an effective antibiotic reagent for Gram-positive bacterial infection;its most common side effect is thrombocytopenia.However,the incidence of thrombocytopenia in patients with acute-on-chronic...BACKGROUND:Linezolid is an effective antibiotic reagent for Gram-positive bacterial infection;its most common side effect is thrombocytopenia.However,the incidence of thrombocytopenia in patients with acute-on-chronic liver failure(ACLF)who underwent linezolid therapy was unclear.The present study was to evaluate the incidence of thrombocytopenia in ACLF and non-ACLF patients treated with linezolid and the risk factors of thrombocytopenia in these patients.METHODS:Thirty-five patients with ACLF who had been subjected to intravenous administration of 600 mg linezolid every 12 hours for more than 7 days were categorized as a ACLF treatment(ACLF-T)group,72 patients without ACLF treated with the same dosage of linezolid were recruited as a non-ACLF treatment(NACLF-T)group,and 70 patients with ACLF without linezolid treatment served as an ACLF control(ACLF-C)group.The incidences of thrombocytopenia in different groups were compared at day 14.Risk factors were investigated using logistic regression analysis.RESULTS:The incidence of thrombocytopenia at day 14 was significantly higher in the ACLF-T group than in the ACLF-C group(20/35 vs 24/70,P=0.025)and in the NACLF-T group(20/35 vs 9/72,P<0.001).Multivariate analysis showed that the ratio of platelet count(day 7/day 0)<1(OR=10.021;P=0.012) and the baseline platelet count(OR=0.985;P=0.036)were independent risk factors of thrombocytopenia at day 14 of linezolid therapy.CONCLUSIONS:The benefits of linezolid treatment should outweigh the risk of thrombocytopenia in patients with ACLF Moreover,it is necessary to closely monitor the platelet count during linezolid therapy especially in the patients with de creased platelet count at day 7 of linezolid therapy.展开更多
Background:For its better differentiated hepatocyte phenotype,C3A cell line has been utilized in bioar-tificial liver system.However,up to now,there are only a few of studies working at the metabolic alter-nations of ...Background:For its better differentiated hepatocyte phenotype,C3A cell line has been utilized in bioar-tificial liver system.However,up to now,there are only a few of studies working at the metabolic alter-nations of C3A cells under the culture conditions with liver failure plasma,which mainly focus on car-bohydrate metabolism,total protein synthesis and ureagenesis.In this study,we investigated the effects of acute liver failure plasma on the growth and biological functions of C3A cells,especially on CYP450 enzymes.Methods:C3A cells were treated with fresh DMEM medium containing 10%FBS,fresh DMEM medium containing 10%normal plasma and acute liver failure plasma,respectively.After incubation,the C3A cells were assessed for cell viabilities,lactate dehydrogenase leakage,gene transcription,protein levels,albu-min secretion,ammonia metabolism and CYP450 enzyme activities.Results:Cell viabilities decreased 15%,and lactate dehydrogenase leakage had 1.3-fold elevation in acute liver failure plasma group.Gene transcription exhibited up-regulation,down-regulation or stability for different hepatic genes.In contrast,protein expression levels for several CYP450 enzymes kept constant,while the CYP450 enzyme activities decreased or remained stable.Albumin secretion reduced about 48%,and ammonia accumulation increased approximately 41%.Conclusions:C3A cells cultured with acute liver failure plasma showed mild inhibition of cell viabilities,reduction of albumin secretion,and increase of ammonia accumulation.Furthermore,CYP450 enzymes demonstrated various alterations on gene transcription,protein expression and enzyme activities.展开更多
Severe deterioration of liver function in patients can be characterized by coagulation disorders, jaundice, hepatic encephalopathy, ascites, and other symptoms. Severe liver injury can develop as acute liver failure, ...Severe deterioration of liver function in patients can be characterized by coagulation disorders, jaundice, hepatic encephalopathy, ascites, and other symptoms. Severe liver injury can develop as acute liver failure, subacute liver failure, acute-on-chronic liver failure, or further worsening of end-stage liver disease [1].展开更多
BACKGROUND The coronavirus disease 2019(COVID-19)caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic.There is still no current effective guidance on the clinical...BACKGROUND The coronavirus disease 2019(COVID-19)caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic.There is still no current effective guidance on the clinical management of COVID-19.Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomodulatory effect in COVID-19 patients.CASE SUMMARY We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells(MenSCs)in the treatment of COVID-19.Moreover,we review the immunomodulation effect including nonspecific and specific immune functions of MenSCs for the therapy of COVID-19.CONCLUSION MenSCs can be helpful to find a promising therapeutic approach for COVID-19.展开更多
基金supported by grants from the China National Science and Technology Major Project(2012ZX10002004 and 2013ZX10002001)Zhejiang CTM Science and Technology Project(2011ZB061)
文摘BACKGROUND:Linezolid is an effective antibiotic reagent for Gram-positive bacterial infection;its most common side effect is thrombocytopenia.However,the incidence of thrombocytopenia in patients with acute-on-chronic liver failure(ACLF)who underwent linezolid therapy was unclear.The present study was to evaluate the incidence of thrombocytopenia in ACLF and non-ACLF patients treated with linezolid and the risk factors of thrombocytopenia in these patients.METHODS:Thirty-five patients with ACLF who had been subjected to intravenous administration of 600 mg linezolid every 12 hours for more than 7 days were categorized as a ACLF treatment(ACLF-T)group,72 patients without ACLF treated with the same dosage of linezolid were recruited as a non-ACLF treatment(NACLF-T)group,and 70 patients with ACLF without linezolid treatment served as an ACLF control(ACLF-C)group.The incidences of thrombocytopenia in different groups were compared at day 14.Risk factors were investigated using logistic regression analysis.RESULTS:The incidence of thrombocytopenia at day 14 was significantly higher in the ACLF-T group than in the ACLF-C group(20/35 vs 24/70,P=0.025)and in the NACLF-T group(20/35 vs 9/72,P<0.001).Multivariate analysis showed that the ratio of platelet count(day 7/day 0)<1(OR=10.021;P=0.012) and the baseline platelet count(OR=0.985;P=0.036)were independent risk factors of thrombocytopenia at day 14 of linezolid therapy.CONCLUSIONS:The benefits of linezolid treatment should outweigh the risk of thrombocytopenia in patients with ACLF Moreover,it is necessary to closely monitor the platelet count during linezolid therapy especially in the patients with de creased platelet count at day 7 of linezolid therapy.
基金supported by grants from the Independent Project Fund of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,the National Key Research and Development Program of China(2016YFC1101304/3)the Key Program of the National Natural Science Foundation of China(81330011)Science Fund for Creative Research Groups of the National Natural Science Foundation of China(81721091).
文摘Background:For its better differentiated hepatocyte phenotype,C3A cell line has been utilized in bioar-tificial liver system.However,up to now,there are only a few of studies working at the metabolic alter-nations of C3A cells under the culture conditions with liver failure plasma,which mainly focus on car-bohydrate metabolism,total protein synthesis and ureagenesis.In this study,we investigated the effects of acute liver failure plasma on the growth and biological functions of C3A cells,especially on CYP450 enzymes.Methods:C3A cells were treated with fresh DMEM medium containing 10%FBS,fresh DMEM medium containing 10%normal plasma and acute liver failure plasma,respectively.After incubation,the C3A cells were assessed for cell viabilities,lactate dehydrogenase leakage,gene transcription,protein levels,albu-min secretion,ammonia metabolism and CYP450 enzyme activities.Results:Cell viabilities decreased 15%,and lactate dehydrogenase leakage had 1.3-fold elevation in acute liver failure plasma group.Gene transcription exhibited up-regulation,down-regulation or stability for different hepatic genes.In contrast,protein expression levels for several CYP450 enzymes kept constant,while the CYP450 enzyme activities decreased or remained stable.Albumin secretion reduced about 48%,and ammonia accumulation increased approximately 41%.Conclusions:C3A cells cultured with acute liver failure plasma showed mild inhibition of cell viabilities,reduction of albumin secretion,and increase of ammonia accumulation.Furthermore,CYP450 enzymes demonstrated various alterations on gene transcription,protein expression and enzyme activities.
基金supported by grants from Key Research and Development Project of Department of Science and Technology of Zhejiang Province(2017C03051)Science Fund for Creative Research Groups of the National Natural Science Foundation of China(81721091)
文摘Severe deterioration of liver function in patients can be characterized by coagulation disorders, jaundice, hepatic encephalopathy, ascites, and other symptoms. Severe liver injury can develop as acute liver failure, subacute liver failure, acute-on-chronic liver failure, or further worsening of end-stage liver disease [1].
基金Zhejiang Basic Public Welfare Research Program,No.LQ20H030012.
文摘BACKGROUND The coronavirus disease 2019(COVID-19)caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic.There is still no current effective guidance on the clinical management of COVID-19.Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomodulatory effect in COVID-19 patients.CASE SUMMARY We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells(MenSCs)in the treatment of COVID-19.Moreover,we review the immunomodulation effect including nonspecific and specific immune functions of MenSCs for the therapy of COVID-19.CONCLUSION MenSCs can be helpful to find a promising therapeutic approach for COVID-19.
